Xencor Company Profile (NASDAQ:XNCR)

About Xencor (NASDAQ:XNCR)

Xencor logoXencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XNCR
  • CUSIP: N/A
  • Web: www.xencor.com
Capitalization:
  • Market Cap: $987.77 million
  • Outstanding Shares: 46,703,000
Average Prices:
  • 50 Day Moving Avg: $23.27
  • 200 Day Moving Avg: $24.32
  • 52 Week Range: $12.51 - $29.38
P/E:
  • Trailing P/E Ratio: 61.61
  • Foreward P/E Ratio: -14.89
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $84.61 million
  • Price / Sales: 11.67
  • Book Value: $6.51 per share
  • Price / Book: 3.25
Profitability:
  • EBIDTA: $15.7 million
  • Net Margins: 39.33%
  • Return on Equity: 22.09%
  • Return on Assets: 15.30%
Debt:
  • Current Ratio: 1.00%
  • Quick Ratio: 1.00%
Misc:
  • Average Volume: 244,246 shs.
  • Beta: 2.21
  • Short Ratio: 7
 

Frequently Asked Questions for Xencor (NASDAQ:XNCR)

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) announced its earnings results on Tuesday, May, 9th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.06. The business earned $4.34 million during the quarter, compared to analysts' expectations of $8.15 million. Xencor had a net margin of 39.33% and a return on equity of 22.09%. View Xencor's Earnings History.

Where is Xencor's stock going? Where will Xencor's stock price be in 2017?

6 brokerages have issued 12 month price objectives for Xencor's stock. Their predictions range from $21.00 to $35.00. On average, they expect Xencor's stock price to reach $28.60 in the next twelve months. View Analyst Ratings for Xencor.

What are analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:

  • 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (4/29/2017)
  • 2. Instinet analysts commented, "We are initiating on XNCR with a Neutral rating and a $21 target price. We recommend stepping to the sidelines in 2017, as we anticipate that XNCR shares will trade flat relative to the biotechnology index over the next 12 months. We note that several near-term catalysts are likely already 'baked in' the current valuation, particularly for the '5871 IgG4- RD program. We believe that a key catalyst'meaningful data for XNCR's bispecific assets'is likely to lead to upside, but that it will occur beyond our 12-month horizon." (3/1/2017)

Who are some of Xencor's key competitors?

Who owns Xencor stock?

Xencor's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (12.44%), FMR LLC (8.09%), Vanguard Group Inc. (3.46%), Perceptive Advisors LLC (3.45%), Redmile Group LLC (3.42%) and State Street Corp (2.13%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

Who sold Xencor stock? Who is selling Xencor stock?

Xencor's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Wellington Management Group LLP, EcoR1 Capital LLC, JPMorgan Chase & Co., Alliancebernstein L.P., Cornerstone Capital Management Holdings LLC. and Morgan Stanley. Company insiders that have sold Xencor stock in the last year include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais and John S Stafford III. View Insider Buying and Selling for Xencor.

Who bought Xencor stock? Who is buying Xencor stock?

Xencor's stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, State Street Corp, Acadian Asset Management LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Vanguard Group Inc., MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. View Insider Buying and Selling for Xencor.

How do I buy Xencor stock?

Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Xencor stock cost?

One share of Xencor stock can currently be purchased for approximately $21.15.

Analyst Ratings

Consensus Ratings for Xencor (NASDAQ:XNCR) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $28.60 (35.22% upside)

Analysts' Ratings History for Xencor (NASDAQ:XNCR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017WedbushReiterated RatingOutperform$29.00HighView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$21.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
11/28/2016Canaccord GenuitySet Price TargetBuy$32.00N/AView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$26.00N/AView Rating Details
10/4/2016Piper Jaffray CompaniesInitiated CoverageOverweight$35.00N/AView Rating Details
5/2/2016Oppenheimer Holdings Inc.Reiterated RatingBuyN/AView Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00N/AView Rating Details
8/5/2015MLV & Co.Reiterated RatingBuy$22.00 -> $29.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Xencor (NASDAQ:XNCR)
Earnings by Quarter for Xencor (NASDAQ:XNCR)
Earnings History by Quarter for Xencor (NASDAQ:XNCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.25)($0.31)$8.15 million$4.34 millionViewListenView Earnings Details
8/2/2016Q216($0.18)$1.13$7.43 million$66.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.27)($0.16)$3.50 million$7.30 millionViewN/AView Earnings Details
3/7/2016Q415($0.30)$0.19$2.50 million$21.80 millionViewN/AView Earnings Details
11/3/2015Q315($0.17)($0.25)$3.57 million$3.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.18)($0.22)$1.90 million$1.01 millionViewN/AView Earnings Details
5/4/2015Q115($0.17)($0.19)$1.90 million$1.49 millionViewListenView Earnings Details
2/19/2015($0.22)($0.04)$1.33 million$5.66 millionViewN/AView Earnings Details
11/10/2014Q3 14($0.19)($0.20)$1.50 million$0.85 millionViewN/AView Earnings Details
7/31/2014($0.19)($0.16)$0.82 millionViewN/AView Earnings Details
5/14/2014Q1 14($0.16)($0.12)$1.71 million$2.20 millionViewN/AView Earnings Details
3/19/2014Q413($0.14)($0.24)$1.71 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xencor (NASDAQ:XNCR)
2017 EPS Consensus Estimate: ($0.92)
2018 EPS Consensus Estimate: ($1.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.17)($0.20)
Q2 20172($0.29)($0.19)($0.24)
Q3 20172($0.32)($0.20)($0.26)
Q4 20172($0.24)($0.21)($0.23)
Q1 20181($0.39)($0.39)($0.39)
Q2 20181($0.41)($0.41)($0.41)
Q3 20181($0.44)($0.44)($0.44)
Q4 20181($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Xencor (NASDAQ:XNCR)
Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 64.14%
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)
Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2017Edgardo Baracchini JrInsiderSell10,568$26.01$274,873.68View SEC Filing  
4/27/2017Edgardo Baracchini JrInsiderSell904$26.04$23,540.16View SEC Filing  
3/16/2017John J. KuchVPSell15,000$24.42$366,300.00View SEC Filing  
3/8/2017Edgardo Baracchini JrInsiderSell1,821$25.00$45,525.00View SEC Filing  
12/6/2016John S Stafford IIIMajor ShareholderSell63,061$27.71$1,747,420.31View SEC Filing  
9/28/2016Edgardo Baracchini JrInsiderSell10,000$25.35$253,500.00View SEC Filing  
9/27/2016John S Stafford IIIMajor ShareholderSell40,000$25.72$1,028,800.00View SEC Filing  
9/2/2016Edgardo Baracchini JrInsiderSell10,000$21.06$210,600.00View SEC Filing  
8/30/2016Bassil I DahiyatInsiderSell40,000$21.80$872,000.00View SEC Filing  
8/26/2016John S Stafford IIIMajor ShareholderSell24,351$21.48$523,059.48View SEC Filing  
8/24/2016John J KuchVPSell25,000$21.95$548,750.00View SEC Filing  
8/23/2016John R DesjarlaisVPSell16,294$21.73$354,068.62View SEC Filing  
8/23/2016John S Stafford IIIMajor ShareholderSell96,828$21.73$2,104,072.44View SEC Filing  
8/16/2016Bassil I DahiyatInsiderSell45,886$22.06$1,012,245.16View SEC Filing  
8/15/2016Bruce L A CarterDirectorSell3,400$22.67$77,078.00View SEC Filing  
8/15/2016John S Stafford IIIMajor ShareholderSell10,000$23.06$230,600.00View SEC Filing  
8/11/2016John S Stafford IIIMajor ShareholderSell30,500$21.87$667,035.00View SEC Filing  
8/10/2016Edgardo Baracchini JrInsiderSell2,500$21.83$54,575.00View SEC Filing  
8/3/2016Edgardo Baracchini, Jr.InsiderSell4,528$20.00$90,560.00View SEC Filing  
8/3/2016John R. DesjarlaisVPSell5,905$20.00$118,100.00View SEC Filing  
7/11/2016Edgardo Baracchini JrInsiderSell1,250$18.13$22,662.50View SEC Filing  
6/28/2016Edgardo Baracchini JrInsiderSell1,250$15.10$18,875.00View SEC Filing  
5/24/2016Bassil I DahiyatCEOSell45,886$13.00$596,518.00View SEC Filing  
4/7/2016Edgardo Baracchini JrInsiderSell3,750$15.00$56,250.00View SEC Filing  
3/17/2016Bassil I DahiyatCEOSell45,886$11.02$505,663.72View SEC Filing  
3/3/2016John R DesjarlaisVPSell14,260$12.01$171,262.60View SEC Filing  
2/1/2016John S Stafford IIIMajor ShareholderSell25$10.79$269.75View SEC Filing  
1/29/2016John S Stafford IIIMajor ShareholderBuy25$10.83$270.75View SEC Filing  
1/4/2016John R. DesjarlaisVPSell1,100$14.13$15,543.00View SEC Filing  
12/17/2015John J KuchVPSell4,781$14.89$71,189.09View SEC Filing  
12/16/2015Paul A. FosterinsiderSell6,025$15.01$90,435.25View SEC Filing  
12/3/2015John S. Stafford IIIDirectorSell30,000$15.13$453,900.00View SEC Filing  
11/25/2015Edgardo Baracchini, Jr.insiderSell2,500$15.00$37,500.00View SEC Filing  
9/3/2015John S Stafford IIIDirectorSell10,000$17.22$172,200.00View SEC Filing  
9/1/2015Edgardo Baracchini, Jr.insiderSell1,250$16.49$20,612.50View SEC Filing  
7/6/2015John S Stafford IIIDirectorSell10,000$22.29$222,900.00View SEC Filing  
7/1/2015Edgardo Baracchini JrInsiderSell2,500$22.24$55,600.00View SEC Filing  
6/16/2015John S Stafford IIIDirectorSell20,000$20.35$407,000.00View SEC Filing  
6/15/2015Bruce L A CarterDirectorSell10,000$19.21$192,100.00View SEC Filing  
6/15/2015Edgardo Baracchini JrInsiderSell1,277$19.85$25,348.45View SEC Filing  
6/12/2015John J KuchVPSell8,756$19.35$169,428.60View SEC Filing  
6/12/2015John S Stafford IIIDirectorSell250,000$19.00$4,750,000.00View SEC Filing  
6/3/2015John S Stafford IIIDirectorSell10,000$18.76$187,600.00View SEC Filing  
6/1/2015Edgardo Baracchini JrInsiderSell1,250$18.14$22,675.00View SEC Filing  
5/26/2015John S Stafford IIIDirectorSell10,000$17.01$170,100.00View SEC Filing  
5/15/2015Edgardo Baracchini JrInsiderSell1,604$15.00$24,060.00View SEC Filing  
8/11/2014John S Stafford IIIDirectorSell124,000$9.37$1,161,880.00View SEC Filing  
12/6/2013John S Stafford IIIDirectorBuy275,000$5.50$1,512,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Xencor (NASDAQ:XNCR)
Latest Headlines for Xencor (NASDAQ:XNCR)
Source:
DateHeadline
finance.yahoo.com logoWorst-Performing Gurus' Stocks
finance.yahoo.com - May 24 at 8:04 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Xencor Inc Lowered by Analyst (XNCR)
www.americanbankingnews.com - May 12 at 7:50 AM
americanbankingnews.com logoXencor Inc (XNCR) to Post Q2 2017 Earnings of ($0.29) Per Share, Wedbush Forecasts
www.americanbankingnews.com - May 12 at 7:50 AM
streetinsider.com logoXencor (XNCR) Announces Orphan Drug Designation from FDA for XmAb5871 to Treat IgG4-Related Disease
www.streetinsider.com - May 11 at 3:20 PM
finance.yahoo.com logoXencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
finance.yahoo.com - May 11 at 3:20 PM
finance.yahoo.com logoEdited Transcript of XNCR earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 3:46 AM
americanbankingnews.com logoXencor Inc (XNCR) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 5:18 PM
finance.yahoo.com logoInvestor Network: Xencor, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 9:38 AM
americanbankingnews.com logoXencor Inc (XNCR) Rating Reiterated by Wedbush
www.americanbankingnews.com - May 10 at 9:18 AM
finance.yahoo.com logoXencor reports 1Q loss
finance.yahoo.com - May 9 at 8:16 PM
americanbankingnews.com logoXencor Inc (XNCR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 9 at 10:31 AM
finance.yahoo.com logoXencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : May 9, 2017
finance.yahoo.com - May 9 at 9:29 AM
americanbankingnews.com logoXencor Inc (XNCR) Expected to Post Quarterly Sales of $8.15 Million
www.americanbankingnews.com - May 7 at 8:16 AM
americanbankingnews.com logoXencor Inc (XNCR) to Release Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:20 AM
americanbankingnews.com logo Analysts Anticipate Xencor Inc (XNCR) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - May 5 at 12:18 PM
americanbankingnews.com logoXencor (XNCR) Given Daily Media Sentiment Rating of 0.17
www.americanbankingnews.com - May 3 at 4:26 PM
americanbankingnews.com logoInsider Selling: Xencor Inc (XNCR) Insider Sells 10,568 Shares of Stock
www.americanbankingnews.com - May 2 at 9:54 PM
finance.yahoo.com logoXencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017
finance.yahoo.com - May 2 at 8:08 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Unlikely to Affect Xencor (XNCR) Stock Price
www.americanbankingnews.com - April 30 at 8:45 AM
americanbankingnews.com logoXencor Inc (XNCR) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 29 at 7:26 AM
americanbankingnews.com logoXencor Inc (XNCR) to Release Earnings on Monday
www.americanbankingnews.com - April 29 at 7:10 AM
americanbankingnews.com logoInsider Selling: Xencor Inc (XNCR) Insider Sells 904 Shares of Stock
www.americanbankingnews.com - April 27 at 9:56 PM
americanbankingnews.com logoXencor (XNCR) Receives Media Impact Rating of 0.31
www.americanbankingnews.com - April 27 at 8:34 AM
finance.yahoo.com logoXencor, Inc. – Value Analysis (NASDAQ:XNCR) : April 26, 2017
finance.yahoo.com - April 26 at 5:22 PM
finance.yahoo.com logoXencor to Present at 42nd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - April 26 at 8:11 AM
finance.yahoo.com logoXencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : April 25, 2017
finance.yahoo.com - April 25 at 7:39 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Affect Xencor (XNCR) Stock Price
www.americanbankingnews.com - April 23 at 11:49 AM
americanbankingnews.com logoXencor Inc (XNCR) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 22 at 5:17 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Unlikely to Affect Xencor (XNCR) Stock Price
www.americanbankingnews.com - April 20 at 9:23 AM
finance.yahoo.com logoXencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
finance.yahoo.com - April 17 at 8:04 AM
americanbankingnews.com logoXencor Inc (XNCR) Expected to Announce Quarterly Sales of $8.15 Million
www.americanbankingnews.com - April 16 at 8:42 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Unlikely to Impact Xencor (XNCR) Stock Price
www.americanbankingnews.com - April 15 at 7:48 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Xencor Inc (XNCR) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - April 14 at 1:20 PM
americanbankingnews.com logoXencor Inc (XNCR) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 14 at 11:51 AM
finance.yahoo.com logoNovartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC
finance.yahoo.com - April 7 at 6:39 PM
nasdaq.com logoXencor Breaks Below 200-Day Moving Average - Notable for XNCR
www.nasdaq.com - April 7 at 1:37 PM
capitalcube.com logoXencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : March 27, 2017
us.rd.yahoo.com - March 27 at 8:03 PM
zacks.com logoIncreased Earnings Estimates Seen for Xencor (XNCR): Can It Move Higher?
www.zacks.com - March 27 at 8:06 AM
zacks.com logoNovartis (NVS) Announces Positive Data on Heart Failure Drug
www.zacks.com - March 20 at 6:50 PM
americanbankingnews.com logoXencor Inc (XNCR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 20 at 11:40 AM
americanbankingnews.com logoJohn J. Kuch Sells 15,000 Shares of Xencor Inc (XNCR) Stock
www.americanbankingnews.com - March 17 at 11:03 PM
finance.yahoo.com logoXencor to Present at Oppenheimer 27th Annual Healthcare Conference
finance.yahoo.com - March 16 at 8:21 AM
finance.yahoo.com logoXENCOR INC Financials
finance.yahoo.com - March 8 at 2:08 AM
streetinsider.com logoXencor (XNCR) Announces Chairman Bruce Carter Will Not Stand ... - StreetInsider.com
www.streetinsider.com - March 7 at 8:10 AM
finance.yahoo.com logoXencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection …
finance.yahoo.com - March 6 at 8:03 PM
us.rd.yahoo.com logoXencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders
us.rd.yahoo.com - March 6 at 8:03 PM
biz.yahoo.com logoXENCOR INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - March 6 at 8:03 PM
biz.yahoo.com logoXENCOR INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 3 at 7:44 AM
us.rd.yahoo.com logoEdited Transcript of XNCR earnings conference call or presentation 28-Feb-17 9:30pm GMT
us.rd.yahoo.com - March 3 at 7:44 AM
us.rd.yahoo.com logoXencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting
us.rd.yahoo.com - March 3 at 7:44 AM

Social

Chart

Xencor (XNCR) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff